Search clinical trials for: Factor Xa Inhibitors

Total 79929 results

Astellas Pharma Inc

Completed

A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet

Healthy Volunteer | Pharmacokinetics of YM150

Japan
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

Atrial Fibrillation

Belgium, United States, Italy, Japan, Taiwan, South Africa, Korea, Republic of, Poland, Chile, Serbia, Israel, France, Netherlands, Denmark, Hungary, Argentina, Australia, China, Spain, New Zealand, Czechia, Bulgaria, Croatia, Malaysia, German... and more
Chiayi Christian Hospital

Recruiting

Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty

Arthroplasty | Venous Thromboembolism

Taiwan
Shanghai Zhongshan Hospital

Recruiting

A Multi-center Study of Apixaban(APPROACH)

Evaluate the Safety and Efficacy of Apixaban

China
Yonsei University

Recruiting

The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)

Atrial Fibrillation Patients With Intermediate Stroke Risk

Korea, Republic of
Institut universitaire de cardiologie et de pneumologie...

Withdrawn

Pharmacokinetics and Pharmacodynamics of Edoxaban Before and After Bariatric Surgery (EXPOSE)

Bariatric Surgery Candidate
Indiana University

Completed

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding ((RAMBLE))

Venous Thromboembolism | Menstruation

United States
Bayer
Janssen Research & Development, LLC

Completed

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban) (FARAONIC)

Heart Failure

Spain
Brigham and Women's Hospital

Completed

Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data

Venous Thromboembolism | Pulmonary Embolism | DVT

United States
Bayer

Completed

A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database

Treatment of Venous Thromboembolism

Japan
Bayer
Janssen Research & Development, LLC

Completed

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE) (JPMS-XAR-VTE)

Venous Thromboembolism

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of DU-176b Aged 80 Years or Older

Atrial Fibrillation

Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region (XANTUS-EL)

Atrial Fibrillation

Colombia, Kazakhstan, Mexico, Russian Federation, Argentina, Azerbaijan, Bahrain, Chile, Egypt, Georgia, Jordan, Kenya, Lebanon, Saudi Arabia, United Arab Emirates, Uruguay, Venezuela
Bayer
Janssen Research & Development, LLC

Completed

Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients (NEURO-XAR)

Stroke | Embolism

Russian Federation
Bayer
Janssen Research & Development, LLC

Completed

Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE) (SOPRANO)

Arthroplasty, Replacement, Knee | Arthroplasty, Replacement, Hip

Russian Federation
Bayer
Janssen Scientific Affairs, LLC

Completed

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication (SAFARI)

Atrial Fibrillation

France
Centre Hospitalier Universitaire de Nīmes

Completed

Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention (Naco_Nîmes)

Atrial Fibrillation

France
Bayer
Janssen Research & Development, LLC

Completed

Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter (X-TRA)

Atrial Fibrillation

France, Germany, Turkey, Russian Federation, Bulgaria, Ukraine, Poland
Bristol-Myers Squibb
Pfizer

Completed

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Healthy Volunteers

United States
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban

Therapeutic Equivalency

Germany
Bristol-Myers Squibb
Pfizer

Completed

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Venous Thrombosis

Australia, Czech Republic, India, Italy, Korea, Republic of, Mexico, United Kingdom, United States, Hong Kong, Spain, France, Argentina, Brazil, Russian Federation, Austria, Denmark, Germany, Israel, Portugal, Romania, Singapore, ... and more
Astellas Pharma Inc

Completed

A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Venous Thromboembolism

Japan
Ottawa Hospital Research Institute

Recruiting

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters (TRIM-Line)

Cancer | Venous Thromboembolism

Canada
Bayer
Janssen Research & Development, LLC

Completed

Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (RITMUS-AF)

Non-valvular Atrial Fibrillation

Italy
Thomas Kander

Completed

The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM

Bleeding | Trauma | Hypothermia | Acidosis

Sweden
Hospital Alemão Oswaldo Cruz
Bayer; Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Brazilian... and other collaborators

Terminated

COVID-19 Antithrombotic Rivaroxaban Evaluation (CARE)

COVID-19

Brazil
Brazilian Clinical Research Institute
Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Hospital do Coracao and other collaborators

Terminated

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 (APOLLO)

Covid19 | Thrombosis

Brazil
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS)

Atrial Fibrillation

Austria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Slovenia, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Poland, Denmark, Sweden, Portugal, Ireland, Norway, Moldova, Republic of, Ukraine
Johns Hopkins University
Bristol-Myers Squibb

Completed

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

Kidney Failure, Chronic | Venous Thromboembolic Disease

United States
Bayer
Janssen Research & Development, LLC; RTI Health Solutions

Completed

Patient and Physician Knowledge of Key Safety Messages

Anticoagulation

Germany, United Kingdom, France, Spain
Bayer
Janssen Research & Development, LLC

Completed

A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants

Thromboembolic Disorders

Germany
Bayer
Janssen Research & Development, LLC

Completed

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

Thrombosis

Canada, United States, Belgium, Spain, Italy, France, Finland, Hungary
Bayer
Janssen Research & Development, LLC

Completed

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Venous Thromboembolism

United States
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis (EINSTEINJr)

Venous Thromboembolism

Switzerland, Spain, United States, Austria, Italy, Russian Federation, United Kingdom, Brazil, Australia, Canada, Hungary, Netherlands, Israel, Poland, Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia (XANAP)

Atrial Fibrillation

Indonesia, Korea, Republic of, Malaysia, Singapore, Thailand, Philippines, Taiwan, Hong Kong, India, Pakistan, Vietnam
Bayer
Janssen Research & Development, LLC

Completed

Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain (HEROIC)

Atrial Fibrillation

Spain
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (BOX-DVT)

Venous Thrombosis

Belgium
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Venous Thrombosis | Pediatrics

Italy, United States, Austria, Australia, Canada, France, Switzerland, Germany, Israel, Ireland
Thomas Jefferson University
Bristol-Myers Squibb

Completed

Apixaban Discontinuation Prior to Major Surgery (ADIOS)

Hemorrhage | Thromboembolism

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects

Anticoagulation
Azienda Ospedaliero Universitaria Maggiore della...

Recruiting

EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation (ORIGAMI II)

Atrial Fibrillation | Fragility

Italy
Sohag University

Not yet recruiting

"ORBIT" Versus "HAS-BLED" Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants.

Patients With Atrial Fibrillation Receiving Oral Anticoagulants
Yonsei University

Recruiting

AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)

Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation

Korea, Republic of
The Second Affiliated Hospital of Chongqing Medical...

Not yet recruiting

A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation

Atrial Fibrillation | Left Atrial Appendage Thrombosis | Rivaroxaban
Bayer
Janssen Research & Development, LLC

Completed

Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function (XARETO)

Non-valvular Atrial Fibrillation (NVAF)

Taiwan
Bayer
Janssen Research & Development, LLC

Completed

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban (EMIR)

Atrial Fibrillation

Spain
Portola Pharmaceuticals

Completed

An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects

Health Volunteers
Brigham and Women's Hospital

Completed

Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Xarelto [SPAF] Post-marketing Surveillance in Japan

Brain Ischemia

Japan
Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company

Completed

Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

Atrial Fibrillation

United Kingdom

Search clinical trials for: Factor Xa Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations